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ABSTRACT 
 
OBJECTIVE:  To evaluate whether prophylactic pregabalin reduces the level of maximum pain 
experienced with mifepristone-misoprostol medical abortion. 
METHODS:  We conducted a randomized, double-blind, placebo-controlled clinical trial of 
women initiating a medical abortion up to 70 days of gestation. After taking mifepristone, 
participants were randomized to a capsule of pregabalin 300 mg or a matched placebo to be 
taken at the time of buccal misoprostol. All participants were dispensed ibuprofen and 
oxycodone with acetaminophen as additional analgesia to be taken as needed. Electronic surveys 
were sent via text message link at six time points over 72 hours to assess the primary outcome of 
maximum pain, as well as secondary outcomes such as analgesic use and adverse effects.  
RESULTS:  From June 2015 to October 2016, 110 women were randomized to receive 300 mg 
of pregabalin or a matched placebo. Demographic characteristics were similar between groups. 
The primary outcome of maximum pain score in the pregabalin group was 5.0 versus 5.5 in the 
placebo group (standard deviations 2.6 and 2.2, respectively; p=0.32). More participants in the 
pregabalin group did not need additional analgesia. No ibuprofen was taken by 27% of the 
pregabalin group versus 12% placebo (p=0.04). No oxycodone with acetaminophen was taken by 
69% of the pregabalin group versus 50% placebo (p=0.04). Satisfaction scores for the abortion 
process were highest in the pregabalin group (very satisfied: 41% versus 22%; p=0.03), as were 
satisfaction scores for the analgesic regimen (very satisfied: 47% versus 22%; p=0.006).  
CONCLUSION: Maximum pain scores were not significantly different between the pregabalin 
and placebo groups, though women who received pregabalin were less likely to require any 
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ibuprofen or oxycodone with acetaminophen, and were more likely to report higher satisfaction 
scores.   
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CHAPTER 1: INTRODUCTION 
 
Medical abortion with mifepristone and misoprostol has been increasing in frequency, 
even as total abortion rates have decreased, with approximately 272,400 medical abortions 
performed in the United States in 2014. Between 2011 and 2014, the total abortion rate in the 
United States declined 12%, while early medical abortions increased from 24 to 31% of all 
nonhospital abortions.1 Providing adequate analgesia at the time of medical abortion is an 
important reproductive health issue.  
Women undergoing a medical abortion with mifepristone and misoprostol consistently 
report moderate to severe pain, with maximum pain scores ranging from seven to eight on an 11-
point scale.2-4 Pain has also been reported to last five or more days for a majority of women.2 
Limited data exists regarding the most effective analgesic regimen, though ibuprofen has been 
found to be superior to acetaminophen and is commonly prescribed.4 There has been no 
difference found between prophylactic or therapeutic use of ibuprofen in reduction of medical 
abortion pain.2 A review of pain management during medical abortion revealed that 75% of 
women also require a narcotic to manage their pain.5 With nationwide goals of reducing narcotic 
use, finding a non-narcotic replacement for analgesia would be ideal. 
Medical abortion is associated with multiple side effects, particularly after misoprostol 
administration. The most common side effects reported after buccal misoprostol include nausea 
(34-75%), vomiting (16-47%), diarrhea (2-61%), weakness (21-58%), headache (2-44%), fever 
(4-48%), and dizziness (12-41%).6 The ideal analgesic regimen would decrease pain while not 
adding any significant side effects. 
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Pregabalin is a gamma-aminobutyric acid (GABA) analog with acute analgesic effects. It 
has 90% bioavailability, reaches its maximum therapeutic effect in less than one hour, and has a 
half-life of 5.5 to 6.7 hours.7 This rapid onset of action could be ideal for co-administration with 
misoprostol, as it would reach its peak effect at the same time as the misoprostol dissolves 
buccally. Co-administration would also simplify the process for patients, instead of having to 
remember to take multiple pills at specific times.  
Pregabalin is increasingly used as a preoperative medication to decrease acute pain. A 
meta-analysis of perioperative pregabalin in 55 trials of different surgical procedures showed a 
significant reduction in pain scores and opioid use compared to placebo. This analysis included a 
wide range of surgical procedures, including laparoscopic cholecystectomy, arthroscopy, spinal 
surgery, and abdominal hysterectomy. There was no significant difference between single 
preoperative dosing and repeated dosing, though increased sedation was seen with multiple doses 
of 300 mg capsules.8 Another meta-analysis specifically of gynecologic procedures demonstrated 
decreased pain scores, decreased total analgesic use, and decreased opioid use with preoperative 
pregabalin, with no difference in adverse effects compared with placebo.9  
The most commonly reported side effects of pregabalin are dizziness (31% pregabalin, 
9% placebo) and somnolence (22% pregabalin, 7% placebo).7,10 Other side effects include 
blurred vision, dry mouth, increased appetite, and constipation.7 In addition to decreasing pain 
scores, preoperative pregabalin use has been associated with decreased post-operative nausea and 
vomiting.8-9 Decreased nausea and increased constipation in the setting of medical abortion could 
potentially decrease the commonly experienced emesis and diarrhea associated with misoprostol 
use. 
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 Many dosages of pregabalin have been studied for analgesia in acute pain events, from 
50 mg to 600 mg, with single dose and multiple dose regimens used. Using	the Dixon sequential 
up-down method with	participants	receiving	intradermal	capsaicin	injections	as	a	marker	of	acute	pain,	the	dose	of	pregabalin	needed	to	decrease	acute	pain	by	30%	was	found	to	be	252	mg.11 Based on the suggestion of a dose-effect gradient, limited by an increase in side 
effects with multiple dosing, we chose to study one 300 mg capsule of pregabalin to maximize 
benefit without incurring additional side effects. At a cost of approximately six dollars per 
capsule without insurance coverage, this could be a cost effective adjunct to standard care. 
Our primary objective was to evaluate whether prophylactic pregabalin, when co-
administered with misoprostol during a medical abortion, reduces maximum pain scores. We 
also hypothesized that pregabalin would decrease the use of adjuvant narcotic pain medication. 
As misoprostol is often associated with nausea, vomiting, and diarrhea, pregabalin was also 
hypothesized to decrease these side effects.  
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CHAPTER 2: MATERIALS AND METHODS 
 
 This was a randomized, double-blind, placebo-controlled trial at the two offices of the 
University of Hawaii Women’s Options Center in Honolulu, Hawaii. The study was approved by 
the University of Hawaii’s Institutional Review Board Committee on Human Studies and 
registered on clinicaltrials.gov: NCT02782169. After consenting to a medical abortion with their 
provider, women were approached by a member of the research staff with information about the 
study. If desired, they provided informed consent for participation. All participants took 
mifepristone 200 mg orally in the office and were dispensed misoprostol 800 mcg to take 
buccally at home 24-48 hours later.  
Eligibility criteria included age 18 years or older, pregnancy up to and including 70 days 
gestation by ultrasound dating, and capability and willingness to receive cellular phone text 
messages and complete multiple electronic surveys over the 72-hour study period. Exclusion 
criteria included a contraindication or allergy to ibuprofen, oxycodone, acetaminophen, or 
pregabalin, current use of a gabapentinoid, alternative misoprostol use (i.e. vaginal 
administration or use in less than 24 hours), inability to speak or read English, or participation in 
this trial during a prior pregnancy.  
Participants were randomized after study consent to one capsule of pregabalin 300 mg or 
placebo to be swallowed immediately prior to buccal placement of misoprostol. The pregabalin 
capsules were over-encapsulated by a research pharmacist at the Daniel K. Inouye College of 
Pharmacy at the University of Hawaii at Hilo. An identical capsule with the same weighted 
excipient was created as a placebo to maintain blinding. An investigator not involved in 
recruitment or patient care created a randomization scheme of varied block sizes (4, 6, and 8), 
	 5	
stratified by location for the two offices used for recruitment, using Sealed Envelope Ltd. 
random sequence generator technology.12  
The computer-generated randomization list was kept in possession of a second 
investigator not involved in the care of trial participants, who placed the allocated study capsule 
in sequentially numbered bags identified only by study identification number. The ordered bags, 
each containing one capsule of pregabalin or placebo as assigned, were then sent to each study 
location for distribution as participants were enrolled. The randomization scheme was kept 
secure from all study personnel and care providers for the duration of the study. No interim 
analysis was performed and all data was collected prior to un-blinding. In case of severe adverse 
events, the second investigator holding the randomization scheme would be able to identify and 
report whether the participant had received pregabalin or placebo.  
A supply of twelve ibuprofen 800 mg tablets and eight oxycodone and acetaminophen 
5/325 mg tablets were dispensed to all participants for analgesia to be taken as needed. Ibuprofen 
was advised for first line use, one tablet (800 mg) every six hours as needed, not to exceed four 
tablets (3200 mg) in 24 hours. Oxycodone with acetaminophen was advised to use for 
breakthrough pain after ibuprofen, one tablet (5/325 mg) every three to four hours as needed. 
Baseline demographic information was collected, including age, race, education level, past 
medical history, medications, gestational age by ultrasound in days, past pregnancy history, and 
anticipated maximum pain from the upcoming abortion on an 11-point numerical rating scale 
(NRS).   
 Data was collected over the 72-hour study period through six online surveys at specified 
time points. Participants were asked to complete the first survey immediately after taking the 
study medication capsule and misoprostol. The link to that first survey was provided at the time 
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of enrollment via SMS text to the participants’ cellular phone, and was also printed on the bag 
containing the study capsule. The survey included an 11-point NRS pain scale, the type and 
number of analgesic tablets taken since mifepristone administration in the office, and a checklist 
of potential side effects including a free text field.  
After completion of the first survey, an SMS text prompt was sent automatically after 2-, 
6-, 12-, 24-, and 72-hours. Each prompt included a link to a new survey that contained the same 
questions as the first as well as a measure of maximal pain by NRS since the previous survey. 
This data point allowed us to collect maximum pain points that may have been missed by the real 
time surveys. At 24-hours post-study medication and misoprostol, a 5-point Likert scale assessed 
satisfaction with the abortion process and analgesia regimen. At 72-hours, maximum pain scores 
were collected for both days since the previous survey. See Appendix A for a copy of each 
survey.  
If participants did not provide survey responses, they were contacted by text (after two 
and six hours without response), phone (after 24 hours), and e-mail (after 72 hours) to provide a 
retrospective report. Participants were remunerated for each response, with a bonus for 
completion of all six surveys. All text message prompts and phone calls were sent from a locked 
cellular phone dedicated to the research trial, held by an investigator at all times. The automated 
SMS prompts were scheduled through the Android application “SMS Scheduler.” 
 The primary outcome was maximum pain score on the 11-point NRS. The trial was 
powered to detect a clinically significant reduction in pain with pregabalin of 1.3 on the 11-point 
NRS.13-14 Based on a trial by Raymond et al using the same dosage of mifepristone, buccal 
misoprostol, ibuprofen with breakthrough narcotic for analgesia, and NRS pain scales, we 
anticipated the maximum pain score in the placebo group to be 7.3 ± 2.2.2 Assuming a normal 
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distribution, a sample size of 92 (46 in each arm) would have 80% power to detect a difference 
in mean pain score of 1.3 with a significance level of 0.05 using a two-sided t-test. If found to 
not follow a normal distribution, a sample size of 84 (42 in each arm) would have the same 
power using a two-sided Mann-Whitney U test. To account for up to a 20% drop-out rate using 
this new method of data collection (text message link to multiple online surveys), we aimed to 
enroll 110 participants.   
 We followed an intention-to-treat analysis, including all participants who provided a 
response for maximum pain, either in real time surveys or in retrospective report. Categorical 
variables were analyzed using Chi square and Fisher exact tests. Continuous variables were 
analyzed with t-tests and Mann-Whitney U tests. Analysis was performed using the Statistical 
Package for Social Sciences (SPSS) software version 24.   
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CHAPTER 3: RESULTS 
 
 From June 2015 to October 2016, a total of 241 women presenting for medical abortion 
at the Women’s Options Centers were screened for inclusion in the trial, with 110 participants 
enrolled and randomized (Figure 1). The most common reasons for exclusion were desire for 
alternative routes of misoprostol administration (n=22) or allergy or contraindication to 
ibuprofen, acetaminophen, or oxycodone (n=14). Three women were excluded because they 
lacked access to a cellular phone or internet, and four women were excluded because they had 
already participated in this trial during a prior pregnancy.  
Three participants were lost to follow-up after randomization, did not provide any survey 
responses, and were excluded from the analysis. One participant in each group did not take the 
study capsule as directed, but were analyzed according to their assigned group. There were no 
reported severe adverse events, and no un-blinding occurred during the trial.  
Baseline demographic characteristics were similar between groups (Table 1). The mean 
age of participants was 27 years (range 18-41), with a mean gestational age of 54 days (range 41-
70). Most women self-identified as Asian, White, or Native Hawaiian, and over one-third 
identified with more than one race. Seventy-seven percent received some education after high 
school. Nineteen percent had a history of depression, and 15% had a history of anxiety. This was 
the first pregnancy for 30% of the participants; 58% were parous, and 45% had a previous 
abortion (37% surgical, 12% medical, and 4% with a history of both).  
Over 93% of women in the trial completed all six surveys (Table 2). The majority of 
surveys were completed within two hours of the scheduled time (77%) (Table 3). When surveys 
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were returned late (18%), retrospective maximum pain scores were provided. Four percent of the 
surveys were never returned.  
Blinding was well maintained, with 59.3% of the pregabalin group correctly identifying 
that they received pregabalin. In the placebo group, 40.8% correctly identified that they received 
a placebo. Fifty nine percent of both groups believed that they received pregabalin (p=0.99). 
 After enrollment and data collection was completed, pain scores were found to follow a 
normal distribution, so pain score analysis was performed using means and t-tests. Participants in 
both groups had a mean anticipated maximum pain score of 6.75 (standard deviations 1.97 for 
pregabalin and 2.04 for placebo; p=0.99) (Table 4). The experienced mean maximum pain scores 
were 5.0 ± 2.6 and 5.5 ± 2.2 in the pregabalin and placebo groups, respectively (p=0.32). The 
ranked pain scores were also not statistically different between study groups (p=0.64) (Figure 2).  
Actual pain scores were lower than expected for 69% of the pregabalin group and 56% of 
the placebo group (p=0.16). Thirty-five percent of participants anticipated severe range pain 
(NRS 8-10), but only 14.5% of the pregabalin group and 17% of the placebo group experienced 
pain of that level (p=0.70). Five percent of women thought that they would experience only mild 
range pain (NRS 0-3), but 27% of the pregabalin group and 13.5% of the placebo group reported 
a maximum of mild pain (p=0.08). The majority (64%) of participants had a maximum of 
moderate range pain (NRS 4-7). 
 When pain scores in the pregabalin group were compared to the placebo group by weeks 
of gestation, women at 7-8 weeks gestation reported lower maximum pain scores with pregabalin 
over placebo (4.9 ± 2.5 versus 6.6 ± 2.0; p=0.04). At 9-10 weeks, maximum pain scores with 
pregabalin were lower as well (3.9 ± 1.6 versus 5.3 ± 2.2), however, the number of participants 
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in this cohort were too small to detect a significant difference, if one exists (n=15). The other 
gestational age groups did not differ significantly. 
Mean pain scores over time are graphically represented in Figure 3. Prior to taking the 
study capsule, participants in the pregabalin group reported statistically higher pain levels, 
though both were less than one on the NRS (0.7 ± 1.3 versus 0.3 ± 0.9; p=0.04). Between hours 
two and six, maximum pain scores were lower in the pregabalin group (3.6 ± 2.5 versus 4.6 ± 
2.3; p=0.04), with the same finding between hours six and twelve (1.9 ± 2.2 versus 2.8 ± 2.0; 
p=0.04). No other time points differed statistically between groups. From hour 12 on, 62-80% of 
participants who received pregabalin reported no pain at each time point. For the placebo group, 
46-82% reported no pain in the same period. Means hovered around one on the NRS starting at 
12 hours until the end of the study period (0.5-1.2 pregabalin, 0.2-1.1 placebo). 
The number of analgesic tablets taken was not normally distributed, and was analyzed by 
nonparametric tests. Median ibuprofen use was one tablet in the pregabalin group and two tablets 
in the placebo group (p=0.34) (Table 5). Both groups had a range of 0-8 tablets. Median 
oxycodone with acetaminophen use was 0 tablets in the pregabalin group and 0.5 tablets in the 
placebo group (p=0.11) (Table 6). Those that received pregabalin used 0-5 tablets of oxycodone 
with acetaminophen, and the placebo group used 0-8 tablets. Analgesic use prior to taking the 
study capsule did not differ between groups, with 30.9% in the pregabalin group taking 
ibuprofen versus 19.2% in the placebo group (p=0.17), and 7.3% versus 3.8% taking oxycodone 
with acetaminophen (p=0.68).  
Pregabalin use was associated with not requiring any additional analgesics. No ibuprofen 
was ever used during the abortion for 27.3% in the pregabalin group compared to 11.5% in the 
placebo group (p=0.04). Those taking pregabalin were also more likely not to take any 
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oxycodone with acetaminophen: 69.1% compared to 50% (p=0.04). To further understand the 
potential analgesic-sparing effect of pregabalin, only analgesics taken after the misoprostol and 
study capsule were considered. Excluding from analysis women who took ibuprofen prior to the 
study capsule, no ibuprofen was ever taken by 39.5% in the pregabalin group and 14.3% in the 
placebo group (p=0.01). Excluding prophylactic oxycodone with acetaminophen users from the 
analysis, 74.5% in the pregabalin group never required a narcotic compared to 52% in the 
placebo group (p<0.02).  
The side effect profiles of each group are shown in Table 7. Participants who received 
pregabalin reported significantly less constipation than placebo (p<0.02), but significantly more 
dizziness (p<0.001). When including only side effects reported after taking the study capsule, 
dizziness was more significant in the pregabalin group (p<0.0001), as was sleepiness (p<0.04) 
and blurred vision (p<0.05), while no difference remained for constipation. There was no 
difference between groups for nausea, vomiting, diarrhea, headache, or dry mouth.  
Graphic representations of side effects over time are represented in Figure 4. For 
pregabalin, the percentage of participants reporting sleepiness and dizziness peaked in the first 6 
hours, and then fell to lower than placebo by 24 hours for the duration of the study. Blurred 
vision similarly peaked for pregabalin in the first 6 hours, coming down to 0% by 24 hours. 
 Satisfaction scores are shown in Table 8. In the pregabalin group, 40.7% were very 
satisfied with the abortion process, compared with 21.6% in the placebo group (p=0.03). 
Satisfaction with analgesia was also higher in the pregabalin group, with 47.2% very satisfied 
with their pain control compared to 21.6% in the placebo group (p=0.006). 
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CHAPTER 4: DISCUSSION 
 
Although this trial did not find a difference between groups in maximum mean pain 
scores, pregabalin was associated with higher satisfaction scores and a greater likelihood of not 
needing any additional analgesics. In the pregabalin group, 27% of women taking pregabalin 
never took ibuprofen, and up to 40% if excluding the users who took ibuprofen prophylactically. 
This result compares to 12% and 14% in the placebo group, respectively (p=0.04 and p=0.01). 
The same is seen with oxycodone with acetaminophen, with 69-75% never using a narcotic in 
the pregabalin group, compared to 50-52% in the placebo group (p=0.04 and p<0.02). This 
finding is in contrast to previous reports of narcotic use in up to 75% of medical abortion 
patients.5 Given the potential for substance use disorders and side effects of narcotics, decreasing 
the need for narcotic analgesia could have substantial public health benefit. This trial also 
provides evidence that if narcotics are prescribed to patients for a medical abortion, a very small 
number of pills should be initially dispensed.  
Maximum pain scores were lower than expected, with a mean maximum of 5.5 in the 
placebo group compared to 7-8 as seen in previous research.2-4 Many studies have used different 
mifepristone doses, routes and dosages of misoprostol, and analgesic regimens, though the trial 
on which the power calculation was based used the same medical abortion regimen and timing as 
this study.2 One potential reason for lower reported pain scores is the real time and short interval 
data collection tool. This allowed for immediate recording of pain scores, not relying on 
retrospective report and potential recall bias. 
Pain duration was shorter than expected based on previous research, with over half of 
participants in both groups being pain free by 12 hours after misoprostol. This is in contrast to a 
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previous study where 60% of participants using the same medical abortion regimen reported pain 
lasting five or more days.2 That study did not report how much pain was present each day, so it is 
possible that the mean pain score was similar to the score of less than one on the NRS that was 
seen here.  
Reported pain scores were also lower than the participants had expected, 1.3-1.8 points 
lower on the NRS than they anticipated at enrollment for placebo and pregabalin, respectively. 
Previous studies have shown pain during a medical abortion to be less than expected in 30-40% 
of cases.2,15 In this study, 56% of the placebo group found the pain to be less than expected, 
compared to 69% in the pregabalin group (p=0.16). This could partially be due to a placebo 
effect, since participants knew they were enrolling in a pain management study. Over half of 
participants in each group believed they received the active study medication, which may have 
also influenced their perception of pain. 
Side effects were high in both groups, particularly gastrointestinal side effects, which are 
commonly experienced in early pregnancy as well as following misoprostol. Over 80% of 
women in the placebo group reported nausea at least once during the study period, almost 60% 
vomiting, and over 50% diarrhea. These numbers were less in the pregabalin group, but not 
significantly. Notably, rates of nausea were highest (60%) prior to taking the misoprostol, 
possibly representing the high baseline rate of nausea in a pregnant population.  
Pregabalin was associated with higher rates of sleepiness, dizziness, and blurred vision, 
which are all known side effects of pregabalin. Each of these side effects peaked at six hours, 
coming down below the rate of the placebo group by 24 hours (or to 0% in the case of blurred 
vision). Despite the increase in sleepiness, dizziness, and blurred vision, the pregabalin group 
still had higher satisfaction scores with the abortion (very satisfied: 41% versus 22%; p=0.03) 
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and their pain control (very satisfied: 47% versus 22%; p=0.006). This cannot be attributed to 
inadequate blinding, as equal numbers of participants in each group believed they received the 
pregabalin (59%; p=0.99). 
Strengths of this study include the randomized, double-blinded, controlled trial design 
and the high follow-up with 93.6% of participants completing all six surveys and only 2.7% lost 
to follow-up. Our combination of text message prompt and online survey data collection tool 
may have contributed to this success. A study by Lim et al showed online diaries to be preferred 
by study participants (51%) as well as most complete, when compared to SMS or paper diaries.16 
Other studies have also shown SMS acceptability, feasibility, and up to a 100% response rate.17-
18 The prompt via SMS allowed participants immediate access to the survey, while protecting 
their privacy by redirecting them to a site where only an identification code was required without 
use of any personal identifiers. Only three women (1.2% of those assessed for eligibility) were 
excluded due to lack of cellular phone or internet access. 
One limitation of this study is that it only included the buccal route of misoprostol 
administration. We specifically included only women taking buccal misoprostol at least 24 hours 
after mifepristone in order to standardize the regimen to what the majority of our patients choose 
and to model the study after the trial on which we based our power calculation.2 Other routes of 
misoprostol administration (oral, vaginal, and sublingual) have shown differing side effect 
profiles, pain scores, and have different timing options for administration after mifepristone.19 
This single regimen may limit generalizability to other modes of misoprostol administration, 
though there is no reason to believe that the mechanism of action for pregabalin as an analgesic 
would be altered. The racial diversity of this trial may also limit its generalizability, with over 
half of participants identifying as Asian and over 30% identifying as Native Hawaiian. 
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All pain studies are limited by the subjective nature of pain reporting.  We chose to use 
multiple data points and real-time assessments to improve validity and mitigate recall bias. When 
studying pain, it may be that a maximum pain score is not the most important outcome. A peak 
value at a moment in time may not truly represent a longitudinal experience. Future research may 
look to other markers, such as pain over time as measured by area under the curve. Perhaps 
surrogate markers such as satisfaction or need for analgesics are more important than a peak 
value as well. While peak pain scores were not decreased with pregabalin, its association with 
increased satisfaction and decreased need for NSAIDs and narcotics along with its ease of 
administration may make it a worthwhile adjunct and deserving of further study. 
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Figure 1: Study flow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Exclusions: Alternative misoprostol regimen (i.e. vaginal or rapid interval) (n=22), allergy to 
analgesia regimen (n=14), age <18 years (n=5), non-English speaking (n=4), prior participation 
in the trial (n=4), no access to cellular phone or internet (n=3). 
† Analysis included the two participants who did not take the study capsule as directed. 
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Table 1: Baseline characteristics of participants 
Demographics Pregabalin (n=55) 
Placebo 
(n=52) P-value 
Age    
     Mean (years) 27.25±5.45 27.19±6.02 0.96 
Race †    
     White 20 (36.4%) 21 (40.4%) 0.67 
     Black 4 (7.3%) 3 (5.8%) 1.00*  
     Asian 34 (61.8%) 27 (51.9%) 0.30 
     Native Hawaiian 17 (30.9%) 17 (32.7%) 0.84 
     Hispanic 10 (18.2%) 7 (13.5%) 0.50 
     Other 4 (7.3%) 3 (5.8%) 1.00* 
     Multiracial 23 (41.8%) 21 (40.4%) 0.88 
Education   0.10 
     Some high school 0 (0%) 3 (5.8%)  
     Graduated high school  8 (14.5%) 13 (25%)  
     Some college 29 (52.7%) 24 (46.2%)  
     Graduated college 15 (27.3%) 12 (23.1%)  
     Post-college degree 3 (5.5%) 0 (0%)  
Mental Health    
     Depression 11 (20%) 10 (19.2%) 0.92 
     Anxiety 7 (12.7%) 9 (17.3%) 0.51 
Pregnancy history    
     First pregnancy 16 (29.1%) 16 (30.8%) 0.85 
     Prior surgical abortion 22 (40%) 18 (34.6%) 0.57 
     Prior medical abortion 6 (10.9%) 7 (13.5%) 0.69 
     Prior miscarriage 13 (23.6%) 11 (22.2%) 0.76 
     Parous 33 (60%) 29 (55.8%) 0.66 
     Prior vaginal delivery 29 (52.7%) 25 (48.1%) 0.63 
     Prior cesarean section 5 (9.1%) 7 (13.5%) 0.47 
Gestational age    
     Mean (days) 53.51±8.16 55.15±6.90 0.26 
     Groups (days)   0.62 
          41-49 19 (34.5%) 14 (26.9%)  
          50-56 14 (25.5%) 19 (36.5%)  
          57-63 15 (27.3%) 12 (23.1%)  
          64-70 7 (12.7%) 7 (13.5%)   
Data are n (%) or mean ± standard deviation. 
Categorical variables were compared with Chi square or Fisher exact tests (*), and continuous 
variables were compared with t-tests.  
† Participants could select more than one race. 
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Table 2: Survey response rate 
Number of  
surveys received 
Pregabalin 
(n=56) 
Placebo 
(n=54) 
Total 
(n=110) 
     0/6  1 (1.8%) 2 (3.7%) 3 (2.7%) 
     1/6  0 (0%) 1 (1.9%) 1 (0.9%) 
     2/6  0 (0%) 0 (0%) 0 (0%) 
     3/6  0 (0%) 0 (0%) 0 (0%) 
     4/6  0 (0%) 1 (1.9%) 1 (0.9%) 
     5/6  1 (1.8%) 1 (1.9%) 2 (1.8%) 
     6/6  54 (96.4%) 49 (90.7%) 103 (93.6%) 
Data are n (%). 
 
 
 
Table 3: Survey response time 
Surveys received  
(each row n=110) On Time 
>2 Hours 
Late 
Never 
submitted 
     0 hours 94 (85.5%) 12 (10.9%) 4 (3.6%) 
     2 hours 90 (81.8%) 15 (13.6%) 5 (4.5%) 
     6 hours 82 (74.5%) 23 (20.9%) 5 (4.5%) 
     12 hours 72 (65.5%) 34 (30.9%) 4 (3.6%) 
     24 hours 90 (81.8%) 17 (15.5%) 3 (2.7%) 
     72 hours 83 (75.5%) 21 (19.1%) 6 (5.5%) 
Data are n (%). 
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Table 4:  Pain scores 
Pain scores (on NRS 0-10) Pregabalin (n=55) 
Placebo 
(n=52) P-value 
Anticipated maximum pain score    
     Mean  6.75±1.97 6.75±2.04 0.99 
     Severity   0.64  
          Mild (0-3) 2 (3.6%) 4 (7.7%)  
          Moderate (4-7) 33 (60%) 31 (59.6%)  
          Severe (8-10) 20 (36.4%) 17 (32.7%)  
Experienced maximum pain score    
     Mean 5.00±2.62 5.46±2.17 0.32 
     Severity   0.21 
          Mild (0-3) 15 (27.3%) 7 (13.5%)  
          Moderate (4-7) 32 (58.2%) 36 (69.2%)  
          Severe (8-10) 8 (14.5%) 9 (17.3%)  
     By gestational age     
          41-49 days 5.26±2.77 4.64±1.78 0.47 
          50-56 days 4.93±2.53 6.63±2.03 0.04 
          57-63 days 5.27±2.96 4.67±2.19 0.56 
          64-70 days 3.86±1.57 5.29±2.21 0.19 
Experienced pain compared to anticipated pain   0.18 
     More than expected 14 (25.5%) 15 (28.9%)  
     Same as expected 3 (5.5%) 8 (15.4%)  
     Less than expected 38 (69.1%) 29 (55.8%)  
Pain scores (mean)    
    Baseline (0 hours) 0.69±1.29 0.25±0.85 0.04 
     0-2 hour maximum 3.52±2.76 3.14±2.51 0.47 
     At 2 hours 2.62±1.93 3.06±1.99 0.25 
     2-6 hour maximum 3.58±2.53 4.56±2.31 0.04 
     At 6 hours 2.29±2.18 2.66±1.87 0.35 
     6-12 hour maximum 1.90±2.17 2.76±1.96 0.04 
     At 12 hours 0.85±1.65 0.76±1.23 0.75 
     12-24 hour maximum 0.89±1.80 1.10±1.33 0.50 
     At 24 hours 0.51±1.51 0.38±0.84 0.60 
     24-48 hour maximum 0.93±1.88 1.12±1.78 0.59 
     48-72 hour maximum 1.19±2.19 0.94±1.63 0.52 
     At 72 hours 0.46±1.50 0.22±0.51 0.27 
NRS = numerical rating scale 
Data are n (%) or mean ± standard deviation. 
Categorical variables were compared with Chi square or Fisher exact tests (*), and continuous 
variables were compared with t-tests. 
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Figure 2: Distribution of maximum pain scores  
 
 
Figure 3: Pain scores over time 
 
* p=0.04 at time points 0, 4, and 9 hours. 
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Table 5: Ibuprofen use 
Ibuprofen 800 mg tablets  Pregabalin (n=55) 
Placebo 
(n=52) P-value 
Prophylactic use 17 (30.9%) 10 (19.2%) 0.17 
Total tablets  
(including prophylactic) 
   
    Median 1 (0-4) 2 (1-3) 0.34 
    Ever use 40 (72.7%) 46 (88.5%) 0.04 
    Number used   0.06 
         0 15 (27.3%) 6 (11.5%)  
         1 13 (23.6%) 16 (30.8%)  
         2 11 (20%) 10 (19.2%)  
         3 2 (3.6%) 11 (21.2%)  
         4 5 (9.1%) 5 (9.6%)  
         5  3 (5.5%) 2 (3.8%)  
         6 3 (5.5%) 1 (1.9%)  
         7 2 (3.6%) 0 (0%)  
         8 1 (1.8%) 1 (1.9%)  
Total tablets (excluding 
prophylactic users) (n=38) (n=42) 
 
    Median 1 (0-2) 1.5 (1-3) 0.06 
    Ever use 23 (60.5%) 36 (85.7%) 0.01 
    Number used   0.15 
         0 15 (39.5%) 6 (14.3%)  
         1 9 (23.7%) 15 (35.7%)  
         2 7 (18.4%) 9 (21.4%)  
         3 1 (2.6%) 5 (12.5%)  
         4 4 (10.5%) 2 (5%)  
         5  1 (2.6%) 2 (5%)  
         6 1 (2.6%) 1 (2.5%)  
         7 0 (0%) 0 (0%)  
         8 0 (0%) 1 (2.5%)  
Data are n (%) or median (interquartile range). 
Categorical variables were compared with the Chi square test, and continuous variables were 
compared with Mann-Whitney U tests. 
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Table 6: Oxycodone with acetaminophen use 
Oxycodone with 
acetaminophen 5/325 mg 
tablet use 
Pregabalin 
(n=55) 
Placebo 
(n=52) P-value 
Prophylactic use 4 (7.3%) 2 (3.8%) 0.68* 
Total tablets  
(including prophylactic) 
   
    Median 0 (0-1) 0.5 (0-1) 0.11 
    Ever use 17 (30.9%) 26 (50%) 0.04 
    Number used   0.07 
          0 38 (69.1%) 26 (50%)  
          1 7 (12.7%) 14 (26.9%)  
          2 3 (5.5%) 7 (13.5%)  
          3  1 (1.8%) 2 (3.8%)  
          4 5 (9.1%) 1 (1.9%)  
          5 1 (1.8%) 1 (1.9%)  
          6 0 (0%) 0 (0%)  
          7 0 (0%) 0 (0%)  
          8 0 (0%) 1 (1.9%)  
Total tablets (excluding 
prophylactic users) (n=51) (n=50)  
    Median 0 (0-1) 0 (0-1) 0.03 
    Ever use 13 (25.5%) 24 (48%) <0.02 
    Number used   0.05 
          0 38 (74.5%) 26 (52%)  
          1 6 (11.8%) 14 (28%)  
          2 2 (3.9%) 7 (14%)  
          3 0 (0%) 1 (2%)  
          4 4 (7.8%) 1 (2%)  
          5 1 (2%) 1 (2%)  
Data are n (%) or median (interquartile range). 
Categorical variables were compared with Chi square or Fisher exact tests (*) and continuous 
variables were compared with Mann-Whitney U tests. 
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Table 7:  Side effects  
 
Data are n (%). 
 
 
 
 
 
 
 
 
 
 
Side effects Pregabalin 
(n=55) 
Placebo 
(n=52) 
P-value 
Ever     
     Nausea 43 (78.2%) 42 (80.8%) 0.74 
     Vomiting 28 (50.9%) 30 (58.8%) 0.41 
     Sleepiness  47 (85.5%) 39 (76.5%) 0.24 
     Dizziness  45 (81.8%) 26 (50%) <0.001 
     Headache 28 (50.9%) 17 (33.3%) 0.07 
     Blurred vision 15 (27.3%) 7 (13.7%) 0.09 
     Diarrhea 28 (50.9%) 29 (56.9%) 0.54 
     Constipation 6 (10.9%) 15 (29.4%) <0.02 
     Dry mouth 22 (40%) 25 (48.1%) 0.40 
After study capsule    
     Nausea 37 (67.3%) 38 (73.1%) 0.51 
     Vomiting 20 (36.4%) 25 (49%) 0.19 
     Sleepy 47 (85.5%) 35 (68.6%) <0.04 
     Dizzy 45 (81.8%) 22 (42.3%) <0.0001 
     Headache 17 (30.9%) 15 (29.4%) 0.87 
     Blurred vision 15 (27.3%) 6 (11.8%) <0.05  
     Diarrhea 25 (45.5%) 28 (54.9%) 0.33 
     Constipation 5 (9.1%) 11 (21.6%) 0.07 
     Dry mouth 21 (38.2%) 21 (40.4%) 0.82 
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Figure 4: Side effects over time 
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Figure 4 (Continued): Side effects over time 
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Figure 4 (Continued): Side effects over time 
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Figure 4 (Continued): Side effects over time 
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Table 8:  Satisfaction scores 
Likert scale 1-5 Pregabalin  Placebo P-value 
Abortion satisfaction  (n=54) (n=51) 0.18  
     Very dissatisfied 1 (1.9%) 0 (0%)  
     Dissatisfied 1 (1.9%) 2 (3.9%)  
     Neutral 12 (22.2%) 18 (35.3%)  
     Satisfied 18 (33.3%) 20 (39.2%)  
     Very satisfied 22 (40.7%) 11 (21.6%) 0.003* 
Analgesia satisfaction (n=53) (n=51) 0.009  
     Very dissatisfied 2 (3.8%) 3 (5.9%)  
     Dissatisfied 3 (5.7%) 0 (0%)  
     Neutral 12 (22.6%) 13 (25.5%)  
     Satisfied 11 (20.8%) 24 (47.1%)  
     Very satisfied 25 (47.2%) 11 (21.6%) 0.006* 
Data are n (%). 
* P-value represents “very satisfied” compared to all other responses.  
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APPENDIX A – STUDY SURVEYS 
Baseline survey (hour 0): 
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Survey #2 (2 hours):  
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Surveys #3 (6 hours) and #4 (12 hours) with identical questions to survey #2, only with different 
time points. 
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Survey #5 (24 hours):  
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Survey #6 (72 hours):  
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